参附注射液治疗急性下壁右室心肌梗死合并低血压临床研究

Clinical Study of Shenfu Injection in the Treatment of Acute Inferior Myocardial Infarction

目的:评价参附注射液治疗急性下壁右室心肌梗死合并低血压状态病人的疗效及安全性。方法:总结我院2014年1月—2016年12月急性下壁右室心肌梗死合并低血压状态病人50例,其中参附组(实验组)25例,多巴胺组(对照组)25例,观察其临床疗效。结果:两组用药后血压回升明显。治疗组升压总有效率为96%,对照组升压总有效率为88%,不良反应发生率在两组之间无明显差异。BNP和CRP的下降幅度实验组大于对照组。结论:参附注射液在治疗急性下壁右室心肌梗死合并低血压状态的患者中效果明显,无副反应发生。

Objective ： To evaluate the efficacy and safety of Shenfu Injection in the treatment of acute inferior and right ventricle myocardial infarction combined with hypoteusion patients. Methods ： To summarize 50 patients with acute inferior and right ventricular myocardial infarction combined with hypotension state in our hospital between January 2014 and December 2016, including Shen^u group （ treatment group ） 25 cases and dopamine group （ control group ） in 25 cases. The clinical efficacy and safety was observed. Results ： The blood pressure of treatment group raised significantly than the control group 96% vs 88% （P〈0.05）, the treatment group showed no adverse reaction. In addition, the level of BNP and CRP decreased significantly in treatment group than that in the control group. Conelusion：Shenfu Injection is efficient and safe in the treatment of acute inferior and right ventricular myocardial infarction with hypotension.